Factors Associated with the Occurrence of Serious Adverse Events Following Immunization Following Administration of Nopv2 in Children Under Five Years of Age in Benin
Background: The new oral polio vaccine type 2 (nOPV2), authorized by WHO in November 2020, was deployed in Benin in 2025 as part of response campaigns against circulating vaccine-derived poliovirus type 2 (cVDPV2). The factors associated with serious adverse events following immunization (AEFI) reported after this c...